|
1
|
Romanelli RG and Stasi C: Recent
advancements in diagnosis and therapy of liver cirrhosis. Curr Drug
Targets. 17:1804–1817. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tsochatzis EA, Bosch J and Burroughs AK:
Liver cirrhosis. Lancet. 383:1749–1761. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kowalski HJ and Abelmann WH: The cardiac
output at rest in Laennec's cirrhosis. J Clin Invest. 32:1025–1033.
1953.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ruiz-del-Arbol L and Serradilla R:
Cirrhotic cardiomyopathy. World J Gastroenterol. 21:11502–11521.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Khare J, Srivastava P, Wadhwa J and Deb P:
Cardiac cirrhosis-an uncommon manifestation of common disease. OGH
Reports. 6:28–30. 2017.
|
|
6
|
Jarkovska D, Bludovska M, Mistrova E,
Krizkova V, Kotyzova D, Kubikova T, Slavikova J, Erek SN,
Djordjevic A and Chottova Dvorakova M: Expression of classical
mediators in hearts of rats with hepatic dysfunction. Can J Physiol
Pharmacol. 95:1351–1359. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li X, Yu S, Li L, Han D, Dai S and Gao Y:
Cirrhosis-related changes in left ventricular function and
correlation with the model for end-stage liver disease score. Int J
Clin Exp Med. 7:5751–5757. 2014.PubMed/NCBI
|
|
8
|
Cesari M, Fasolato S, Rosi S and Angeli P:
Cardiac dysfunction in patients with cirrhosis: Is the systolic
component its main feature? Eur J Gastroenterol Hepatol.
27:660–666. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sampaio F, Pimenta J, Bettencourt N,
Fontes-Carvalho R, Silva AP, Valente J, Bettencourt P, Fraga J and
Gama V: Systolic and diastolic dysfunction in cirrhosis: A
tissue-Doppler and speckle tracking echocardiography study. Liver
Int. 33:1158–1165. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gregolin CS, do Nascimento M, Borges de
Souza SL, Ferreira Mota GA, Bomfim GF, de Azevedo Melo Luvizotto R,
Sugizaki MM, Zanati Bazan SG, Salomé de Campos DH, Dias MC, et al:
Myocardial dysfunction in cirrhotic cardiomyopathy is associated
with alterations of phospholamban phosphorylation and IL-6 levels.
Arch Med Res. 52:284–293. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Silvestre OM, Farias AQ, Ramos DS, Furtado
MS, Rodrigues AC, Ximenes RO, de Campos Mazo DF, Yoshimura Zitelli
PM, Diniz MA, Andrade JL, et al: β-blocker therapy for cirrhotic
cardiomyopathy: A randomized-controlled trial. Eur J Gastroenterol
Hepatol. 30:930–937. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Accornero F, van Berlo JH, Correll RN,
Elrod JW, Sargent MA, York A, Rabinowitz JE, Leask A and Molkentin
JD: Genetic analysis of connective tissue growth factor as an
effector of transforming growth factor β signaling and cardiac
remodeling. Mol Cell Biol. 35:2154–2164. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xiao H, Li H, Wang JJ, Zhang JS, Shen J,
An XB, Zhang CC, Wu JM, Song Y, Wang XY, et al: IL-18 cleavage
triggers cardiac inflammation and fibrosis upon β-adrenergic
insult. Eur Heart J. 39:60–69. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ziemssen T and Siepmann T: The
investigation of the cardiovascular and sudomotor autonomis nervous
system-a review. Front Neurol. 10(53)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yang CH, Ting WJ, Day CH, Ju DT, Yeh YL,
Chung LC, Tsai FJ, Tsai CH, Tsai Y and Huang CY: SHSST cyclodextrin
complex prevents the fibrosis effect on CCl4-induced
cirrhotic cardiomyopathy in rats through TGF-β pathway inhibition
effects. Int J Mol Sci. 15:8037–8048. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Clark JD, Gebhart GF, Gonder JC, Keeling
ME and Kohn DF: The 1996 guide for the care and use of laboratory
animals. ILAR J. 38:41–48. 1997.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kasarala G and Tillmann H: Standard liver
tests. Clin Liver Dis (Hoboken). 8:13–18. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Lo RC and Kim H: Histopathological
evaluation of liver fibrosis and cirrhosis regression. Clin Mol
Hepatal. 23:302–307. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Moller S and Henriksen JH: Cirrhotic
cardiomyopathy. J Hepatol. 53:179–190. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Naqvi IH, Mahmood K, Naeem M, Vashwani AS
and Ziaullah S: The heart matters when the liver shatters!
Cirrhotic cardiomyopathy: Frequency, comparison, and correlation
with severity of disease. Prz Gastroenterology. 11:247–256.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Berzigotti A: Advances and challenges in
cirrhosis and portal hypertension. BMC Med. 15(200)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chayanupatkul M and Liangpunsakul S:
Cirrhotic cardiomyopathy: Review of pathophysiology and treatment.
Hepatol Int. 8:308–315. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang Y, Hu Y, Zeng Z, Li Y, Su H, Li Y,
Wang R, Zhang M, Yang Y and Deng J: Influence of androgen on
myocardial apoptosis and expression of myocardial IR and IRS1 in
chronic heart failure rat models. Mol Med Rep. 17:1057–1064.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gassanov N, Caglayan E, Semmo N,
Massenkeil G and Er F: Cirrhotic cardiomyopathy: A cardiologist's
perspective. World J Gastroenterol. 20:15492–15498. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xiao J, Wang F, Wong NK, He J, Zhang R,
Sun R, Xu Y, Liu Y, Li W, Koike K, et al: Global liver disease
burdens and research trends: Analysis from a Chinese perspective. J
Hepatol. 71:212–221. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wu L, Ong S, Talor MV, Barin JG,
Baldeviano GC, Kass DA, Bedja D, Zhang H, Sheikh A, Margolick JB,
et al: Cardiac fibroblasts mediate IL-17A-driven inflammatory
dilated cardiomyopathy. J Exp Med. 211:1449–1464. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fede G, Privitera G, Tomaselli T, Spadaro
L and Purrello F: Cardiovascular dysfunction in patients with liver
cirrhosis. Ann Gastroenterol. 28:31–40. 2015.PubMed/NCBI
|
|
28
|
Karagiannakis DS, Papatheodoridis G and
Vlachogiannakos J: Recent advances in cirrhotic cardiomyopathy. Dig
Dis Sci. 60:1141–1151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu H, Jayakumar S, Traboulsi M and Lee
SS: Cirrhotic cardiomyopathy: Implications for liver
transplantation. Liver Transpl. 23:826–835. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Saner FH, Neumann T, Canbay A, Trechmann
JW, Hartmann M, Goerlinger K, Bertram S, Beckebaum S, Cicinnati V
and Paul A: High brain-natriuretic peptide level predicts cirrhotic
cardiomyopathy in liver transplant patients. Transpl Int.
24:425–432. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang YY and Lin HC: The heart:
Pathophysiology and clinical implications of cirrhotic
cardiomyopathy. J Chin Med Assoc. 75:619–623. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zaky A and Lang JD: Cirrhosis-associated
cardiomyopathy. J Anesth Clin Res. 3:1–7. 2012.
|
|
33
|
Ortiz-Olvera NX, Castellanos-Pallares G,
Gómez-Jiménez LM, Cabrera-Muñoz ML, Méndez-Navarro J, Morán-Villota
S and Dehesa-Violante M: Anatomical cardiac alterations in liver
cirrhosis: An autopsy study. Ann Hepatol. 10:321–326.
2011.PubMed/NCBI
|
|
34
|
Naveed M, Han L, Hasnat M, Baig MMFA, Wang
W, Mikrani R, Zhiwei L, Sembatya KR, Xie D and Zhou X: Suppression
of TGP on myocardial remodeling by regulating the NF-κB pathway.
Biomed Pharmacother. 108:1460–1468. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Briasoulis A, Mallikethi-Reddy S, Palla M,
Alesh I and Afonso L: Myocardial fibrosis on cardiac magnetic
resonance and cardiac outcomes in hypertrophic cardiomyopathy: A
meta-analysis. Heart. 101:1406–1411. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jou C, Shah R, Figueroa A and Patel JK:
The role of inflammatory cytokines in cardiac arrest. J Intensive
Care Med. 35:219–224. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bageghni SA, Hemmings KE, Zava N, Denton
CP, Porter KE, Ainscough JFX, Drinkhill MJ and Turner NA: Cardiac
fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy
via a putative paracrine interleukin-6 signaling mechanism. FASEB
J. 32:4941–4954. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Soresi M, Giannitrapani L, D'Antona F,
Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N and
Montalto G: Interleukin-6 and its soluble receptor in patients with
liver cirrhosis and hepatocellular carcinoma. World J
Gastroenterol. 12:2563–2568. 2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu X, Li C, Zhu J, Li W and Zhu Q:
Dysregulation of FTX/miR-545 signaling pathway downregulates Tim-3
and is responsible for the abnormal activation of macrophage in
cirrhosis. J Cell Biochem: Oct 10, 2018 (Epub ahead of print).
|
|
40
|
Pagourelias ED, Sotiriou P, Papadopoulos
CE, Cholongitas E, Giouleme O and Vassilikos V: Left ventricular
myocardial mechanics in cirrhosis: A speckle tracking
echocardiographic study. Echocardiography. 33:223–232.
2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Blendis L and Wong F: The hyperdynamic
circulation in cirrhosis: An overview. Pharmacol Ther. 89:221–231.
2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Moller S, Hove JD, Dixen U and Bendtsen F:
New insights into cirrhotic cardiomyopathy. Int J Cardiol.
167:1101–1108. 2013.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Muñoz-Ortega MH, Llamas-Ramírez RW,
Romero-Delgadillo NI, Elías-Flores TG, Tavares-Rodríguez EJ,
Campos-Esparza MR, Cervantes-García D, Muñoz-Fernández L,
Gerardo-Rodríguez M and Ventura-Juárez J: Doxazasin treatment
attenuates carbon tetrachloride-induced liver fibrosis in hamsters
through a decrease in transforming growth factor β secretion. Gut
Liver. 10:101–108. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
44
|
Communal C, Singh M, Menon B, Xie Z,
Colucci WS and Singh K: Beta1integrins expression in adult rat
ventricular myocytes and its role in the regulation of
beta-adrenergic receptorstimulated apoptosis. J Cell Biochem.
89:381–388. 2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Parvaneh S, Howe CL, Toosizadeh N,
Honarvar B, Slepian MJ, Fain M, Mohler J and Najafi B: Regulation
of cardiac autonomic nervous system control across frailty
statuses: A systematic review. Gerontology. 62:3–15.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ma G, Wang Y, Hou D, Liu J, Zhang J, Xu L,
Wang H, Zhao W, Zhang Y and Zhang L: Association of autoantibodies
against the M2-muscarinic receptor with long-term outcomes in
peripartum cardiomyopathy patients: A 5-year prospective study. J
Cardiol. 74:251–257. 2019.PubMed/NCBI View Article : Google Scholar
|
